Status:
COMPLETED
The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
Lead Sponsor:
Bayer
Conditions:
Contraception
Eligibility:
FEMALE
21-44 years
Phase:
NA
Brief Summary
To evaluate the safety and long-term (approximately one year) effectiveness of the Essure System for Permanent Birth Control ESS505 device in preventing pregnancy.
Detailed Description
This study has previously been posted by Conceptus, Inc. After acquiring Conceptus, Inc., Bayer is now the sponsor of the trial.
Eligibility Criteria
Inclusion
- Female with age range 21 to 44 years
- Subjects who are seeking permanent contraception
- Subjects with body weight within range of 40 - 136 kilograms (90-300 pounds)
- Subjects willing to accept the risk of pregnancy occurring while relying solely on the ESS505 as contraception
- Subjects for whom medical history and physical examination indicates bilateral viable and patent fallopian tubes
- Subjects who are able to comply with the protocol required follow-up visits (e.g., 3 month clinic visit, and the 12-month telephone interview)
- Subjects who provide written informed consent prior to enrolment
- Subjects who have sufficient mental capability to provide clinically relevant and reliable feedback regarding her experience wearing the device
- Subjects agrees that her anonymised personal data will be made available to Study sponsor, requisite regional and international regulatory bodies
- Subjects for whom there are no contraindications for use as described in the ESS505 Instructions for Use (IFU)
Exclusion
- Subjects with known proximal tubal occlusion in either fallopian tube
- Subjects who have undergone fallopian tube sterilization procedure
- Subjects diagnosed with unicornuate uterus
- Subjects diagnosed with endometrial or myometrial pathology which may prevent fallopian tube ostia assessment
- Subjects scheduled to undergo concomitant intrauterine procedures at the time of ESS505 placement; IUD removal is not considered a concomitant procedure
- Subjects suspected of being or confirmed pregnant
- Subjects post-partum or has undergone pregnancy termination ≤6 weeks of scheduled ESS505 placement
- Subjects diagnosed with active upper or lower pelvic infection
- Subjects for whom there are one or more contraindications for use as described in the ESS505 IFU
- Subjects have positive pre-procedure pregnancy test
Key Trial Info
Start Date :
January 31 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2014
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT01861886
Start Date
January 31 2013
End Date
September 30 2014
Last Update
March 21 2017
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Hoofddorp, Netherlands, 2134 TM
2
Nieuwegein, Netherlands, 3435 CM
3
Tiel, Netherlands, 4002 WP
4
Zwolle, Netherlands, 8025 AB